Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

EXOZYMES INC.

EXOZ · Nasdaq · CIK 0002010788 · Healthcare · Biotechnology

INSIDER SIGNAL

35.3 / 100

1 buyers · 5 purchase transaction lines · $6.4K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+1.2 / 25
Role+13.0 / 20
Recency+4.1 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: Chief Executive Officer (CEO, chair and 10% owners score lowest)

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Heltzen MichaelChief Executive Officer
○●●
Perriman Damien AlanChief Commercial Officer
○
Korman Tyler PazChief Scientific Officer
○
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Heltzen Michael · $6.4K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-08-25–2026-08-26

Roles in the peak window: Chief Executive Officer. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

35.3 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 35.6
  2. 35.6
  3. 35.5
  4. 35.4
  5. 35.3

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

5Purchases
2Sales
8Other Form 4 lines
9SEC filings · 365 days
BUYING5 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER3 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-14.9%
3M
-17.6%
6M
-55.1%
12M
-59.8%

Volatility & liquidity

Volatility
86.3%
Beta
—
Avg daily value
USD 35,575

Valuation

Market cap
USD 48.7M
P/E
—

Fundamentals

Profit margin
—
ROE
-269.6%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-13 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
18,469
Previous report
20,419
Avg daily volume
8,995
Days to cover
2.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-26Heltzen MichaelPurchase (P)Common Stock505USD 7.48USD 3,775SEC filing ↗
2026-08-25Heltzen MichaelPurchase (P)Common Stock350USD 7.51USD 2,630SEC filing ↗
2025-07-02Heltzen MichaelPurchase (P)Common Stock1,040USD 10.22USD 10,629SEC filing ↗
2025-01-17Heltzen MichaelPurchase (P)Common Stock1,767USD 10.78USD 19,048SEC filing ↗
2025-01-16Heltzen MichaelPurchase (P)Common Stock121USD 10.72USD 1,297SEC filing ↗
2024-11-15Heltzen MichaelPurchase (P)Common Stock1,984USD 11.10USD 22,022SEC filing ↗

Form 4 evidence

15 transaction lines in the latest 365-day window; 24 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-26Heltzen MichaelPurchase (P)Common Stock505USD 7.48USD 3,775SEC filing ↗
2026-08-25Heltzen MichaelPurchase (P)Common Stock350USD 7.51USD 2,630SEC filing ↗
2026-08-19Heltzen MichaelAward / grant (A)Common Stock8,841USD 6.40USD 56,582SEC filing ↗
Show recent Form 4 evidence (12 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-26Heltzen MichaelPurchase (P)Common Stock505USD 7.48USD 3,775SEC filing ↗
2026-08-25Heltzen MichaelPurchase (P)Common Stock350USD 7.51USD 2,630SEC filing ↗
2026-08-19Heltzen MichaelAward / grant (A)Common Stock8,841USD 6.40USD 56,582SEC filing ↗
2026-08-19Perriman Damien AlanOption exercise / conversion (M)Common Stock19,612USD —USD —SEC filing ↗
2026-08-19Korman Tyler PazOption exercise / conversion (M)Common Stock32,964USD —USD —SEC filing ↗
2026-04-09Korman Tyler PazSale (S)COMMON STOCK750USD 10.53USD 7,897SEC filing ↗
2026-04-08Korman Tyler PazSale (S)COMMON STOCK750USD 10.04USD 7,530SEC filing ↗
2026-04-01Perriman Damien AlanAward / grant (A)Restricted Stock Grant for Common Stock62,759USD 0.00USD 0SEC filing ↗
2026-04-01Perriman Damien AlanAward / grant (A)COMMON STOCK8,887USD 8.44USD 75,006SEC filing ↗
2026-04-01Opgenorth Paul HideoAward / grant (A)COMMON STOCK3,999USD 8.44USD 33,752SEC filing ↗
2026-04-01Nawaz FouadAward / grant (A)COMMON STOCK5,999USD 8.44USD 50,632SEC filing ↗
2026-04-01Korman Tyler PazAward / grant (A)COMMON STOCK5,332USD 8.44USD 45,002SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerEXOZ
CIK0002010788
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history24 transaction lines from 2024-11-08 to 2026-08-26
9 P purchase lines · 2 S sale lines · 13 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.